{
    "name": "methoxsalen",
    "comment": "Rx",
    "other_names": [
        "8MOP",
        "Oxsoralen",
        "Oxsoralen Ultra",
        "Uvadex"
    ],
    "classes": [
        "Antifungals",
        "Topicals",
        "Antipsoriatics",
        "Systemic",
        "Antipsoriatics",
        "Topical",
        "Psoralens"
    ],
    "source": "https://reference.medscape.com/drug/8mop-oxsoralen-methoxsalen-343585",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: not known whether excreted in breast milk; use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known whether excreted in breast milk; use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Injection ",
                    "description": [
                        "Should be prescribed only by physicians who have competence in both the diagnosis and treatment of cutaneous T-cell lymphoma and the UVAR Photopheresis System"
                    ]
                },
                {
                    "type": "PO",
                    "description": [
                        "Use with UV radiation should be done only by physicians competent in photochemistry and in the diagnosis and treatment of psoriasis and vitiligo",
                        "Reserve photochemotherapy for patients with severe, recalcitrant, disabling psoriasis unresponsive to other therapy",
                        "Risks include ocular damage, aging of the skin, and skin cancer",
                        "Do not interchange Oxsoralen-Ultra (Methoxsalen Soft Gelatin Capsules) with Oxsoralen or 8-MOP (Methoxsalen Hard Gelatin Capsules), as Oxsoralen-Ultra has a greater bioavailability and earlier photosensitization"
                    ]
                },
                {
                    "type": "Topical lotion",
                    "description": [
                        "Potent drug capable of producing severe burns if used improperly",
                        "Should be applied only by a healthcare provider under controlled conditions"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to psoralen compounds",
                "Photosensitive disease states (SLE, etc.), history of melanoma, squamous cell carcinoma (SCC), aphakia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Dosages of hard and soft capsules are NOT interchangeable",
                "Tests prior to treatment and then q6-12mth: ophthalmologic exam, CBC, ANA, LFTs, RFTs",
                "Overdose &/or overexposure could lead to serious burns from UVA or sunlight",
                "Use appropriate shielding of eyes and unaffected skin during treatment",
                "Increased risk of SCC, basal cell carcinoma (esp. if history of radiation treatment or arsenic treatment)",
                "Wear UVA-absorbing sunglasses for 24 hr post-treatment to avoid cataract formation",
                "Avoid sun exposure 8 hr post-treatment",
                "Hepatic disease (hepatic metabolism), cardiac disease (heat stress)",
                "Severe photosensitivity can occur; advise patients to wear UVA absorbing, wrap-around sunglasses and cover exposed skin or use a sunblock (SP 15 or higher), and avoid all exposure to sunlight for twenty-four (24) hours following photopheresis treatment",
                "Do not sunbathe for 24 hr prior to treatment & for 48 hr post-treatment",
                "Thromboembolic events, such as pulmonary embolism and deep vein thrombosis, reported with administration through photopheresis systems for treatment of patients with graft-versus-host disease, a disease for which methoxsalen is not approved"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "fedratinib",
            "description": {
                "common": "methoxsalen will increase the level or effect of fedratinib by  Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "methoxsalen will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pirfenidone",
            "description": {
                "common": "methoxsalen will increase the level or effect of pirfenidone by  affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Use of strong CYP1A2 inhibitors should be discontinued before initiating pirfenidone and avoided during treatment; if strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "methoxsalen increases levels of pomalidomide by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "methoxsalen will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "methoxsalen will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "methoxsalen increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "methoxsalen, bendroflumethiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "methoxsalen, chlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "methoxsalen, chlorpromazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "methoxsalen, chlorthalidone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "methoxsalen, cyclopenthiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "methoxsalen, demeclocycline.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "methoxsalen, doxycycline.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "methoxsalen increases levels of eluxadoline by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP1A2 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "methoxsalen will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "methoxsalen will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "methoxsalen, fluphenazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "methoxsalen, griseofulvin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "methoxsalen, hydrochlorothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "methoxsalen, indapamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "methoxsalen will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "methoxsalen increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "methoxsalen will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "methoxsalen increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mavacamten",
            "description": {
                "common": "methoxsalen will increase the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Inititiation of weak CYP2C19 inhibitors may require decreased mavacamten dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "methoxsalen, methyclothiazide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylene blue",
            "description": {
                "common": "methoxsalen, methylene blue.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "methoxsalen, metolazone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "methoxsalen will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minocycline",
            "description": {
                "common": "methoxsalen, minocycline.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxytetracycline",
            "description": {
                "common": "methoxsalen, oxytetracycline.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentoxifylline",
            "description": {
                "common": "methoxsalen will increase the level or effect of pentoxifylline by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "methoxsalen, perphenazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "methoxsalen, prochlorperazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promazine",
            "description": {
                "common": "methoxsalen, promazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "methoxsalen, promethazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfadiazine",
            "description": {
                "common": "methoxsalen, sulfadiazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "methoxsalen, sulfamethoxazole.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfisoxazole",
            "description": {
                "common": "methoxsalen, sulfisoxazole.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tasimelteon",
            "description": {
                "common": "methoxsalen will increase the level or effect of tasimelteon by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Avoid coadministration; potentially large increase in tasimelteon exposure and greater risk of adverse reactions with strong CYP1A2 inhibitors"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "methoxsalen will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbinafine",
            "description": {
                "common": "methoxsalen will increase the level or effect of terbinafine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "methoxsalen, tetracycline.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "methoxsalen, thioridazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "methoxsalen will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "methoxsalen, trifluoperazine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "methoxsalen will increase the level or effect of warfarin by  Other (see comment). Use Caution/Monitor. Warfarin's less potent R-enantiomer is metabolized in part by CYP3A4 (and also CYP1A2 and CYP2C19). Monitor INR more frequently if coadministered with inhibitors of these isoenzymes and adjust warfarin dose if needed. "
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "food",
            "description": {
                "common": "food increases levels of methoxsalen by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Admin. each oral dose of methoxsalen at same time w/respect to food."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "methoxsalen will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "methoxsalen will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Mild",
            "percent": "24-48"
        },
        {
            "name": "moderate erythema x",
            "percent": null
        },
        {
            "name": "hrs",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Pruritis",
            "percent": null
        },
        {
            "name": "Edema",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Malaise",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Hypopigmentation",
            "percent": null
        },
        {
            "name": "Bullae formation",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Herpes simplex",
            "percent": null
        },
        {
            "name": "Uritcaria",
            "percent": null
        },
        {
            "name": "GI disturbances",
            "percent": null
        },
        {
            "name": "Leg cramps",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Extension of psoriasis",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Allergic reaction",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Dysgeusia",
            "percent": null
        }
    ]
}